PDCD1 and thyroid gland carcinoma: Recently, M2-TAMs were shown to downregulate METTL3 in thyroid cancer cells and promote immunosuppressive TME through the transfer of extracellular vesicles (EVs), reversing the immunosuppressive effect of M2-TAMs that mediates resistance to anti-PD-1 therapy in thyroid cancer [128].